JPMorgan Chase & Co. Reiterates Underweight Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “underweight” rating reaffirmed by equities researchers at JPMorgan Chase & Co. in a research note issued to investors on Wednesday, MarketBeat reports.

Several other research firms also recently commented on GSK. Shore Capital restated a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Berenberg Bank cut their target price on GSK from GBX 1,820 ($23.07) to GBX 1,600 ($20.28) and set a “buy” rating for the company in a research report on Friday, November 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,850 ($23.45) target price on shares of GSK in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.89).

GSK Price Performance

Shares of LON:GSK opened at GBX 1,334 ($16.91) on Wednesday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The firm has a market capitalization of £54.43 billion, a PE ratio of 1,182.91, a PEG ratio of 1.24 and a beta of 0.31. GSK has a 1-year low of GBX 1,282.50 ($16.26) and a 1-year high of GBX 1,823.50 ($23.11). The business’s 50 day moving average is GBX 1,411.08 and its 200-day moving average is GBX 1,530.52.

Insider Transactions at GSK

In related news, insider Elizabeth (Liz) McKee Anderson purchased 446 shares of GSK stock in a transaction that occurred on Monday, September 23rd. The stock was purchased at an average cost of GBX 2,051 ($26.00) per share, with a total value of £9,147.46 ($11,595.21). Also, insider Jonathan Symonds purchased 7,150 shares of GSK stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of GBX 1,394 ($17.67) per share, with a total value of £99,671 ($126,341.74). Insiders bought 7,604 shares of company stock valued at $10,893,038 over the last three months. Company insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.